½ÃÀ庸°í¼­
»óǰÄÚµå
1560964

Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀå º¸°í¼­ : ±â¼ú, Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Lateral Flow Assay Market Report by Technique, Product, Application, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 144 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀå ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 104¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2032³â±îÁö 155¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â 4.4%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.

Lateral Flow Assay(LFA)´Â º¹ÀâÇÑ È¥ÇÕ¹°¿¡¼­ ºÐ¼®¹°ÁúÀ» °ËÃâÇϰí Á¤·®ÇÏ´Â Á¾ÀÌ ±â¹Ý Ç÷§ÆûÀÔ´Ï´Ù. Ÿ¾×, ¼Òº¯, ¶¡, Ç÷û, Ç÷Àå, Ç÷¾×°ú °°Àº »ýü »ùÇÃÀ» °Ë»çÇÏ´Â µ¥ À¯¿ëÇÕ´Ï´Ù. ±× °á°ú ƯÁ¤ ¾à¹°, Ç×ü, À¯ÀüÀÚ ÁõÆøÀÇ Á¤¼º ¹× Á¤·®Àû °ËÃâÀ» À§ÇØ º´¿ø ¹× ÀÓ»ó ½ÇÇè½Ç¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ LFA´Â Àúºñ¿ë, °£´Ü, ½Å¼Ó, ÈÞ´ë°¡ °£ÆíÇÑ °ËÃâ Àåºñ Á¦Á¶¿¡ µµ¿òÀÌ µÇ¹Ç·Î »ýÀÇÇÐ, ³ó¾÷, ½Äǰ, ȯ°æ °úÇÐ ºÐ¾ß¿¡¼­ »ç¿ëµÇ¾î Àü ¼¼°è¿¡¼­ Å« Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù.

Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀå µ¿Çâ :

Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ ȯÀÚ »ùÇÃÀ» °Ë»ç½Ç·Î º¸³»´Â ´ëü ¼ö´Ü¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) °Ë»ç¸¦ ½±°Ô ¼öÇàÇÒ ¼ö ÀÖ´Â ±¤¹üÀ§ÇÑ °Ë»ç ½Ã¼³°ú ¼÷·ÃµÈ ÀÇ·áÁøÀÇ ºÎÁ·°ú ÇÔ²² ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀ̸ç, LFA ŰƮ´Â Æí¸®Çϰí ÀÛ°í ÈÞ´ë°¡ °£ÆíÇϸç ÃÖ¼ÒÇÑÀÇ ±³À°À¸·Î °ü¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼¼Ã´, ³ÃÀå º¸°ü, Àü󸮰¡ ÇÊ¿ä ¾ø´Â ¿ø½ºÅÜ ºÐ¼®À¸·Î ÀÛµ¿ÇÕ´Ï´Ù. ¶ÇÇÑ Á¤¼ºÀû ¶Ç´Â ¹ÝÁ¤·®Àû °á°ú¸¦ ¾òÀ» ¼ö ÀÖ°í, °³¹ß ½Ã°£ÀÌ »ó´ëÀûÀ¸·Î ª°í, ¹Ì¸® ¹èÄ¡¸¦ ÁغñÇÒ ¼ö ÀÖÀ¸¸ç, °Ë»ç ÀýÂ÷¸¦ ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² È¿°úÀûÀÎ Ä¡·á¸¦ À§ÇØ »õ·Î¿î Áø´Ü ¹æ¹ýÀÌ ÇÊ¿äÇÑ Àü¿°º´ÀÇ À¯ÇàÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡ ´õÇØ °¨¿°º´ÀÇ È®»ê, Áø´Ü ¹× ¿¹¹æ¿¡ ´ëÇÑ ÀνÄÀÌ Å©°Ô ³ô¾ÆÁø °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÌ »õ·Î¿î ½ÅÈ£ °­È­ ±â¼úÀ» µµÀÔÇÏ¿© Á¤·®È­ ½Ã½ºÅÛ ¹× µ¿½Ã °ËÃâÀ» °³¼±Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°è Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • COVID-19°¡ ¼¼°è Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀåÀÇ ±â¼úº° ºÐ¼® ½ÃÀå ÇöȲÀº?
  • ¼¼°è Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀåÀÇ Á¦Ç°º° ±¸¼ººñ´Â?
  • ¼¼°è Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀåÀÇ ¿ëµµ´Â?
  • ¼¼°è Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀåÀÇ ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼® ½ÃÀå ÇöȲÀº?
  • ¼¼°è Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ ¾îÇÁ·ÎÄ¡
    • Åé´Ù¿î ¾îÇÁ·ÎÄ¡
  • Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Å×Å©´Ðº°

  • »÷µåÀ§Ä¡ ¾î¼¼ÀÌ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • °æÀï ¾î¼¼ÀÌ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¸ÖƼÇ÷º½º ŽÁö ¾î¼¼ÀÌ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • ŰƮ¿Í ½Ã¾à
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Ãø¹æÀ¯µ¿ ¸®´õ
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ºÎ¹®
      • µðÁöÅÐ/¸ð¹ÙÀÏ ¸®´õ
      • º¥Ä¡Å¾ ¸®´õ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ÀÓ»ó½ÃÇè
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ºÎ¹®
      • °¨¿°Áõ °Ë»ç
      • ½ÉÀå ¸¶Ä¿ °Ë»ç
      • ÀӽŰú »ý½Ä ´É·Â °Ë»ç
      • ÄÝ·¹½ºÅ×·Ñ °Ë»ç/ÁöÁú °³¿ä
      • ¾à¹° ³²¿ë °Ë»ç
      • ±âŸ
    • ½ÃÀå ¿¹Ãø
  • ¼öÀÇ Áø´Ü
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ½Äǰ ¾ÈÀü°ú ȯ°æ ½ÃÇè
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÀǾàǰ °³¹ß°ú ǰÁú ½ÃÇè
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø°ú Áø·á¼Ò
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Áø´Ü °Ë»ç½Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ȨÄɾî
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀïÀÇ Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ÀÇ °³¿ä
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Biomerieux SA
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche AG
    • Hologic Inc.
    • Merck KGAA
    • Perkinelmer Inc.
    • Qiagen N.V.
    • Quidel Corporation
    • Siemens Healthineers AG(Siemens AG)
    • Thermo Fisher Scientific Inc.
KSA 24.10.04

The global lateral flow assay market size reached US$ 10.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.4% during 2024-2032.

Lateral flow assay (LFA) is a paper-based platform that detects and quantifies analytes in complex mixtures. It assists in testing biological samples of saliva, urine, sweat, serum, plasma, blood, and other fluids. As a result, it is widely employed in hospitals and clinical laboratories for the qualitative and quantitative detection of specific agents, antibodies, and gene amplification. Besides this, as it also aids in producing low-cost, simple, rapid, and portable detection devices that are utilized in biomedicine, agriculture, food, and environmental sciences, LFA is gaining immense popularity across the globe.

Lateral Flow Assay Market Trends:

Due to the coronavirus disease (COVID-19) outbreak, there is a rise in the need for an alternative of sending patient samples to the laboratory. This, in confluence with the lack of extensive laboratory facilities or trained health workers to easily conduct polymerase chain reaction (PCR) tests, represents one of the key factors bolstering the growth of the market. LFA kits are convenient, smaller, portable, and can be controlled with minimal training. They act as a one-step assay that does not require washing steps, refrigeration, and pretreatment. They also faster test procedures that offer qualitative or semi-quantitative results, take a relatively short time for development, and allow the preparation of batches in advance. Besides this, there is an increase in the prevalence of infectious diseases that require new diagnostic methods for effective treatment. This, along with the significantly rising awareness programs to enhance the spread of infections, diagnosis, and prevention, is contributing to market growth. Furthermore, leading players are introducing novel signal enhancement techniques and improving quantification systems and simultaneous detection, which is creating a favorable market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global lateral flow assay market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on technique, product, application, and end user.

Breakup by Technique:

  • Sandwich Assays
  • Competitive Assays
  • Multiplex Detection Assays

Breakup by Product:

  • Kits and Reagents
  • Lateral Flow Readers
    • Digital/Mobile Readers
    • Benchtop Readers

Breakup by Application:

  • Clinical Testing
    • Infectious Disease Testing
    • Cardiac Marker Testing
    • Pregnancy and Fertility Testing
    • Cholesterol Testing/Lipid Profile
    • Drug Abuse Testing
    • Others
  • Veterinary Diagnostics
  • Food Safety and Environment Testing
  • Drug Development and Quality Testing

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Home Care
  • Pharmaceutical and Biotechnology Companies
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Merck KGAA, Perkinelmer Inc., Qiagen N.V., Quidel Corporation, Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1. How big is the global lateral flow assay market?
  • 2. What is the expected growth rate of the global lateral flow assay market during 2024-2032?
  • 3. What are the key factors driving the global lateral flow assay market?
  • 4. What has been the impact of COVID-19 on the global lateral flow assay market?
  • 5. What is the breakup of the global lateral flow assay market based on the technique?
  • 6. What is the breakup of the global lateral flow assay market based on the product?
  • 7. What is the breakup of the global lateral flow assay market based on the application?
  • 8. What is the breakup of the global lateral flow assay market based on the end user?
  • 9. What are the key regions in the global lateral flow assay market?
  • 10. Who are the key players/companies in the global lateral flow assay market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Lateral Flow Assay Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technique

  • 6.1 Sandwich Assays
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Competitive Assays
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiplex Detection Assays
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Kits and Reagents
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Lateral Flow Readers
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Digital/Mobile Readers
      • 7.2.2.2 Benchtop Readers
    • 7.2.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Clinical Testing
    • 8.1.1 Market Trends
    • 8.1.2 Key Segments
      • 8.1.2.1 Infectious Disease Testing
      • 8.1.2.2 Cardiac Marker Testing
      • 8.1.2.3 Pregnancy and Fertility Testing
      • 8.1.2.4 Cholesterol Testing/Lipid Profile
      • 8.1.2.5 Drug Abuse Testing
      • 8.1.2.6 Others
    • 8.1.3 Market Forecast
  • 8.2 Veterinary Diagnostics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Food Safety and Environment Testing
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Drug Development and Quality Testing
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Home Care
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Pharmaceutical and Biotechnology Companies
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Becton Dickinson and Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Biomerieux SA
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bio-Rad Laboratories Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Danaher Corporation
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Hologic Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck KGAA
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Perkinelmer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Qiagen N.V.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Quidel Corporation
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Siemens Healthineers AG (Siemens AG)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Thermo Fisher Scientific Inc.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦